| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3851 |
| Trial ID | NCT06365671 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Co-treatment | autologous stem-cell transplantation |
| Location approved | China |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Single-Arm Clinical Study of CD19 CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors |
| Year | 2024 |
| Country | China |
| Company sponsor | Ruijin Hospital |
| Other ID(s) | ASCT-CART |
| Cohort 1 | |||||||||
|
|||||||||